ArticlePLoS neglected tropical diseases2011
A screen against Leishmania intracellular amastigotes: comparison to a promastigote screen and identification of a host cell-specific hit.
Article in PLoS neglected tropical diseases, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 92 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
92 citing papers in PubMed, 2 syntheses or guidelines pooled it, 221 citations in OpenAlex.
- A Systematic Review of Curcumin and its Derivatives as Valuable Sources of Antileishmanial Agents.Acta parasitologica · 2021Pooled it
- Safety and efficacy of allylamines in the treatment of cutaneous and mucocutaneous leishmaniasis: A systematic review.PloS one · 2021Pooled it
- Probing 5-Nitroimidazole-Triazole Hybrids as Potential Anti-Kinetoplastid Agents: Synthesis and In Vitro Efficacy.ChemMedChem · 2026Article
- Evaluation of the safety and immunogenicity of a peptide vaccine against canine leishmaniosis: a double-blind, multicenter, controlled clinical trial in dogs.The veterinary quarterly · 2025Article
- Desmuramylpeptide, a NOD2 agonist, enhanced immune response and parasite clearance inFuture medicinal chemistry · 2025Article
- Article
- Antiparasitic and Antifungal Activities of Cetyl-Maritima, a NewAntibiotics (Basel, Switzerland) · 2025Article
- Evaluation of Beauvericin's activity and mode of action against all life stages ofFrontiers in cellular and infection microbiology · 2025Article
- Leishmaniases: Strategies in treatment development.Parasite (Paris, France) · 2025Review
- Promising Antileishmanial Activity ofMolecules (Basel, Switzerland) · 2024Article
- In Vitro and Ex Vivo Synergistic Effect of Pyrvinium Pamoate Combined with Miltefosine and Paromomycin againstTropical medicine and infectious disease · 2024Article
- Potential Effects of Essential Oil fromMicroorganisms · 2024Article
- PLGA Nanoparticles as New Drug Delivery Systems in Leishmaniasis Chemotherapy: A Review of Current Practices.Current medicinal chemistry · 2024Review
- Imidazo[1,2-ACS omega · 2023Article
- Design, synthesis, electrochemistry and anti-trypanosomatid hit/lead identification of nitrofuranylazines.RSC medicinal chemistry · 2023Article
- Systematic Exploration of Functional Group Relevance for Anti-Leishmanial Activity of Anisomycin.Biomedicines · 2023Article
- Novel Schiff bases of Vanillin: potent inhibitors of macrophage harboredJournal of parasitic diseases : official organ of the Indian Society for Parasitology · 2023Article
- Antileishmanial evaluation of triazole-butenolide conjugates: design, synthesis,RSC medicinal chemistry · 2023Article
- Antiparasitic Activity of Fluorophenyl-Substituted Pyrimido[1,2-Biomedicines · 2023Article
- Miltefosine and Nifuratel Combination: A Promising Therapy for the Treatment ofInternational journal of molecular sciences · 2023Article
32 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
The ability to screen compounds in a high-throughput manner is essential in the process of small molecule drug discovery. Critical to the success of screening strategies is the proper design of the assay, often implying a compromise between ease/speed and a biologically relevant setting. Leishmaniasis is a major neglected disease with limited therapeutic options. In order to streamline efforts for the design of productive drug screens against Leishmania, we compared the efficiency of two screening methods, one targeting the free living and easily cultured promastigote (insect-infective) stage, the other targeting the clinically relevant but more difficult to culture intra-macrophage amastigote (mammal-infective) stage. Screening of a 909-member library of bioactive compounds against Leishmania donovani revealed 59 hits in the promastigote primary screen and 27 in the intracellular amastigote screen, with 26 hits shared by both screens. This suggested that screening against the promastigote stage, although more suitable for automation, fails to identify all active compounds and leads to numerous false positive hits. Of particular interest was the identification of one compound specific to the infective amastigote stage of the parasite. This compound affects intracellular but not axenic parasites, suggesting a host cell-dependent mechanism of action, opening new avenues for anti-leishmanial chemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.